ClinicalTrials.Veeva

Menu

Endometrial Malignancy in Breast Cancer Patients With or Without AUB (TamAUB)

U

University of Campania "Luigi Vanvitelli"

Status

Completed

Conditions

Endometrial Neoplasms

Treatments

Diagnostic Test: Ultrasound
Diagnostic Test: Hysteroscopy

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

In order to assess the hysteroscopic, histopathologic, and ultrasonographic aspects of uterine monitoring in postmenopausal breast cancer patients with or without abnormal uterine bleeding (AUB), as well as to calculate the risk of endometrial cancer in women with or without AUB.

Full description

20-25% of postmenopausal women undergoing tamoxifen (TAM) therapy develop polyps, according to recent studies. Many large (>2 cm) and molecularly changed uterine polyps are usually seen in these women. Furthermore, a number of studies have demonstrated that TAM therapy raises the risk of endometrial cancer in both premenopausal and postmenopausal women. Studies suggest that women who use TAM may also have an increase in the prevalence of uterine sarcomas. In addition, the duration of TAM administration appears to increase the risk of endometrial cancer and uterine sarcoma.

This multicentric cohort study will compare the ultrasonographic, hysteroscopic, and histopathologic findings in postmenopausal women treated for breast cancer with or without AUB in order to increase the robustness of a still ambiguous literature on the subject. It will estimate the risk of endometrial cancer in women with AUB according to various covariates related to the breast neoplasm or the ultrasonographic and hysteroscopic features.

Enrollment

283 patients

Sex

Female

Ages

43 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • In case of AUB: ultrasonographic endometrial thickness >5 mm at transvaginal ultrasound
  • In case of non-AUB group ultrasonographic suspicion of endometrial or myometrial abnormalities

Exclusion criteria

  • severe comorbidities (cardiovascular, metabolic, endocrine, and immunological disorders)
  • receiving any other form of pharmacologic therapy

Trial design

283 participants in 2 patient groups

Breast cancer patients with abnormal uterine bleeding
Description:
* Transvaginal ultrasonography * Outpatient Hysteroscopy
Treatment:
Diagnostic Test: Hysteroscopy
Diagnostic Test: Ultrasound
Breast cancer patients without abnormal uterine bleeding
Description:
* Transvaginal ultrasonography * Outpatient Hysteroscopy
Treatment:
Diagnostic Test: Hysteroscopy
Diagnostic Test: Ultrasound

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems